Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
LETTER
Kiana Winslow, Ayla Gerk, Kee Park, Gabriella Hyman
No abstract text is available yet for this article.
September 20, 2023: Lancet
#2
JOURNAL ARTICLE
Seong Jin Jo, Raymond Jaihyun Cho
No abstract text is available yet for this article.
September 19, 2023: Lancet
#3
JOURNAL ARTICLE
Akimichi Morita, Bruce Strober, A David Burden, Siew Eng Choon, Milan J Anadkat, Slaheddine Marrakchi, Tsen-Fang Tsai, Kenneth B Gordon, Diamant Thaçi, Min Zheng, Na Hu, Thomas Haeufel, Christian Thoma, Mark G Lebwohl
BACKGROUND: Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety of spesolimab for GPP flare prevention. METHODS: This multicentre, randomised, placebo-controlled, phase 2b trial was done at 60 hospitals and clinics in 20 countries. Eligible study participants were aged between 12 and 75 years with a documented history of GPP as per the European Rare and Severe Psoriasis Expert Network criteria, with a history of at least two past GPP flares, and a GPP Physician Global Assessment (GPPGA) score of 0 or 1 at screening and random assignment...
September 19, 2023: Lancet
#4
JOURNAL ARTICLE
Nisha Sajnani, Nils Fietje
No abstract text is available yet for this article.
September 19, 2023: Lancet
#5
REVIEW
Martin J van den Bent, Marjolein Geurts, Pim J French, Marion Smits, David Capper, Jacoline E C Bromberg, Susan M Chang
The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of rarer CNS tumour types exists. The classification of these tumours is increasingly based on molecular diagnostics, which is reflected in the extensive molecular foundation of the recent WHO 2021 classification of CNS tumours. Resection as extensive as is safely possible is the cornerstone of treatment in most gliomas, and is now also recommended early in the treatment of patients with radiological evidence of histologically low-grade tumours...
September 19, 2023: Lancet
#6
JOURNAL ARTICLE
Justin Koonin, Shraddha Mishra, Amandeep Saini, Misimi Kakoti, Emma Feeny, Devaki Nambiar
No abstract text is available yet for this article.
September 19, 2023: Lancet
#7
JOURNAL ARTICLE
A breakthrough in measuring violence against children is a powerful step in protecting human rights.
Omar Abdi, Najat Maalla M'jid
No abstract text is available yet for this article.
September 18, 2023: Lancet
#8
JOURNAL ARTICLE
Jeffrey Sachs, Henry B Perry
No abstract text is available yet for this article.
September 18, 2023: Lancet
#9
JOURNAL ARTICLE
Jane K O'Hara, Carolyn Canfield
No abstract text is available yet for this article.
September 15, 2023: Lancet
#10
JOURNAL ARTICLE
Transforming women's, children's, and adolescents' health and wellbeing through primary health care.
(no author information available yet)
No abstract text is available yet for this article.
September 15, 2023: Lancet
#11
JOURNAL ARTICLE
Karoliina Jalava, Ville Sallinen, Hanna Lampela, Hanna Malmi, Ingeborg Steinholt, Knut Magne Augestad, Ari Leppäniemi, Panu Mentula
BACKGROUND: Appendicectomy remains the standard treatment for appendicitis. No international consensus exists on the surgical urgency for acute uncomplicated appendicitis, and recommendations vary from surgery without delay to surgery within 24 h. Longer in-hospital delay has been thought to increase the risk of perforation and further morbidity. Therefore, we aimed to compare the rate of appendiceal perforation in patients undergoing appendicectomy scheduled to two different urgencies (<8 h vs <24 h)...
September 14, 2023: Lancet
#12
JOURNAL ARTICLE
Elisabeth M L de Wijkerslooth, Anne Loes van den Boom, Bas P L Wijnhoven
No abstract text is available yet for this article.
September 14, 2023: Lancet
#13
REVIEW
Michael Reid, Yvan Jean Patrick Agbassi, Nimalan Arinaminpathy, Alyssa Bercasio, Anurag Bhargava, Madhavi Bhargava, Amy Bloom, Adithya Cattamanchi, Richard Chaisson, Daniel Chin, Gavin Churchyard, Helen Cox, Claudia M Denkinger, Lucica Ditiu, David Dowdy, Mark Dybul, Anthony Fauci, Endalkachew Fedaku, Mustapha Gidado, Mark Harrington, Janika Hauser, Petra Heitkamp, Nick Herbert, Ani Herna Sari, Philip Hopewell, Emily Kendall, Aamir Khan, Andrew Kim, Irene Koek, Sergiy Kondratyuk, Nalini Krishnan, Chu-Chang Ku, Erica Lessem, Erin V McConnell, Payam Nahid, Matt Oliver, Madhukar Pai, Mario Raviglione, Theresa Ryckman, Marco Schäferhoff, Sachin Silva, Peter Small, Guy Stallworthy, Zelalem Temesgen, Kitty van Weezenbeek, Anna Vassall, Gustavo E Velásquez, Nandita Venkatesan, Gavin Yamey, Armand Zimmerman, Dean Jamison, Soumya Swaminathan, Eric Goosby
No abstract text is available yet for this article.
September 13, 2023: Lancet
#14
JOURNAL ARTICLE
Busisiwe Beko, Jennifer Furin
No abstract text is available yet for this article.
September 13, 2023: Lancet
#15
JOURNAL ARTICLE
Marc G Besselink, Johanna W Wilmink
No abstract text is available yet for this article.
September 11, 2023: Lancet
#16
JOURNAL ARTICLE
Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Christelle De La Fouchardière, Andrew Dean, Igor Kiss, Woo Jin Lee, Thorsten O Goetze, Eric Van Cutsem, A Scott Paulson, Tanios Bekaii-Saab, Shubham Pant, Richard A Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen M O'Reilly
BACKGROUND: Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). METHODS: NAPOLI 3 was a randomised, open-label, phase 3 study conducted at 187 community and academic sites in 18 countries worldwide across Europe, North America, South America, Asia, and Australia...
September 11, 2023: Lancet
#17
REVIEW
Jennifer L Taylor-Cousar, Paul D Robinson, Michal Shteinberg, Damian G Downey
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a new era of cystic fibrosis management has emerged-one in which scientific principles translated from the bench to the bedside have enabled us to potentially treat the basic defect in the majority of children and adults with cystic fibrosis, with a resultant burgeoning adult cystic fibrosis population. However, the long-term effects of these therapies on the multiple manifestations of cystic fibrosis are still under investigation...
September 8, 2023: Lancet
#18
REVIEW
Simon Y Graeber, Marcus A Mall
With the 2019 breakthrough in the development of highly effective modulator therapy providing unprecedented clinical benefits for over 90% of patients with cystic fibrosis who are genetically eligible for treatment, this rare disease has become a front runner of transformative molecular therapy. This success is based on fundamental research, which led to the identification of the disease-causing CFTR gene and our subsequent understanding of the disease mechanisms underlying the pathogenesis of cystic fibrosis, working together with a continuously evolving clinical research and drug development pipeline...
September 8, 2023: Lancet
#19
JOURNAL ARTICLE
Lucy Perrem, Felix Ratjen
No abstract text is available yet for this article.
September 8, 2023: Lancet
#20
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
September 8, 2023: Lancet
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
